FWIW I agree that at the moment ELTP is not in a high growth phase. Vyvanse and the Adderalls are competing well in their markets, but the other generic companies are fighting for a piece of that market as well. I am curious if Elite's generic Norco and Percocet are winning market share in the states they are selling those products. As I have mentioned, they are not available in NYS because Elite has decided not to pay the NYS opioid excise tax. Methadone and methotrexate are both recent launches in competitive markets. My guess is Kirko is cutting into those markets but the well established competitors are certainly fighting back. IMHO the Oxycontin litigation offers the best near term chance for high growth to resume. GLTA.
Market Data 
Markets 
AI
